Medibact GuidesShop at Medibact

Stacking Module

CJC-1295 Stacking Module

CJC-1295 is the GHRH analog half of the most-copied stack in this catalog. Its stacking picture turns almost entirely on one distinction that is frequently lost: whether you have the DAC version or not, because that changes the dosing schedule the whole stack is built around.

CJC-1295 Guide at MedibactCJC-1295 calculatorPeptide Stacking Guide

Educational use only — not medical advice. This page summarizes information reported in published research and community practice for educational purposes. It is not medical advice and not a recommendation to use any compound. Any doses, schedules, or combinations shown are examples of what has been reported, not instructions for you. Many peptides described here are research compounds that are not FDA-approved for the uses discussed and may be investigational or restricted. Effects, risks, and legal status vary; individual needs and results vary. Consult a qualified, licensed healthcare professional before making any decision. Do not use this content to diagnose, treat, or dose yourself.

How to think about stacking CJC-1295

  • CJC-1295 with DAC has a multi-day duration; CJC-1295 without DAC is Mod GRF 1-29 and lasts minutes to hours. A protocol written for one does not transfer to the other, and vendors are inconsistent about which they are selling.
  • It is a GHRH analog. The complementary partner is a ghrelin-receptor secretagogue, not another GHRH analog.
  • No-DAC versions are reported fasted and often at bedtime to align with the nocturnal GH pulse; DAC versions are described as schedule-flexible because the long half-life smooths the pulse out.
  • No controlled trial has studied CJC-1295 combined with anything.

Combinations in detail

CJC-1295 + Ipamorelin

GHRH analog + selective GHS-R1a secretagogue
Why it is proposed
The canonical GH-axis pairing, and the clearest two-pathway rationale in this catalog: CJC-1295 raises GHRH signaling while Ipamorelin acts at the ghrelin receptor. Ipamorelin is the selective choice, reported not to drive cortisol or prolactin the way older secretagogues can.
What is reported in practice
Commonly reported together in a single subcutaneous administration, frequently at bedtime for no-DAC versions. Community protocols describe roughly equal microgram amounts, though that convention is not evidence-based.
Cautions specific to this combination
If you have the DAC version the bedtime rationale largely disappears, and combining a long-acting GHRH analog with a short pulse-based secretagogue changes what the stack is doing. Confirm which version you have first.

CJC-1295 + GHRP-2 or GHRP-6

GHRH analog + older-generation secretagogue
Why it is proposed
The same two-pathway logic with an older secretagogue. GHRP-2 is reported as more potent on GH release; GHRP-6 is reported to drive appetite markedly.
What is reported in practice
Reported as a lower-cost alternative to the Ipamorelin pairing.
Cautions specific to this combination
Both older secretagogues are reported to affect cortisol and prolactin more than Ipamorelin, which is the usual reason Ipamorelin displaced them in this pairing. GHRP-6's appetite effect is substantial and often unwanted.

GH-axis plus repair

CJC-1295 + Ipamorelin + BPC-157 + TB-500
Why it is proposed
Adds the repair pairing on the premise that GH-axis support and local tissue repair act on different things entirely.
What is reported in practice
Reported as separate vials on their own schedules — the GH pair typically at night, the repair compounds independently.
Cautions specific to this combination
Four compounds, no combination data, and four separate reconstitutions with different scales. This is where arithmetic errors accumulate.

What to avoid, and why

  • Pairing two GHRH analogs (Sermorelin, CJC-1295, Mod GRF 1-29, Tesamorelin) is described as redundant rather than additive — they act at the same receptor. Mod GRF 1-29 is CJC-1295 without the DAC modification, so combining those two is close to running one compound against itself.
  • Assuming a vial labelled CJC-1295 is the DAC version. The two behave differently enough that the stack's schedule depends on it.
  • Adding a second secretagogue alongside Ipamorelin — same receptor, no added mechanism.

Related reading

CJC-1295 + Ipamorelin — CJC-1295 + IpamorelinThe Peptide Stacking GuideAll stacking pages

Every combination described here is reported practice or mechanism-level reasoning. No controlled trial has studied any of these combinations, and nothing on this page is a personal protocol, a dose recommendation, or medical advice.